Should I Buy NNNN? NNNN 2026 Analysis

Should You Buy Anbio Biotechnology (NNNN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

25.650

1 Day change

6.61%

52 Week Range

55.650

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: the setup suggests a higher chance of a near-term pullback despite today’s +6.43% pop.
Price is still below the key pivot/resistance area (29.03), and momentum is not yet bullish (MACD still negative).
No Intellectia trading signals (AI Stock Picker / SwingMax) to justify an aggressive entry today.
With no fresh news/catalysts and neutral fund/insider activity, the risk/reward is not compelling at current levels.

Technical Analysis

Trend/Momentum: MACD histogram is negative (-0.473) but contracting, implying bearish momentum is weakening, not reversed.
RSI (6): 48.61 (neutral), showing no strong oversold bounce signal.
Moving Averages: converging MAs suggest consolidation/indecision rather than a confirmed uptrend.
Key levels: Current price 24 is below Pivot 29.03 (overhead resistance). Support S1 ~19.12; resistance begins at Pivot 29.03 then R1 ~38.94.
Pattern-based forward look: Similar-pattern model indicates ~80% chance of -3.77% next day; modest positive bias over next month (+5.4%), implying better odds after a dip than chasing today.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Positive Catalysts

- Today’s strong regular-session move (+6.43%) could attract short-term momentum interest.
- Model-based projection is modestly positive over the next month (+5.4%), suggesting upside potential if price stabilizes and reclaims the pivot (29.03).
- MACD bearish momentum is weakening (negative but contracting), which can precede a trend turn if price confirms.

Neutral/Negative Catalysts

- High near-term downside skew from pattern-based signal: ~80% chance of a decline next day (-3.77%), unfavorable for buying immediately.
- Price remains below the key pivot (29.03), implying overhead resistance and an unconfirmed trend reversal.
- No news in the last week: lacks event-driven catalysts to sustain a breakout.
- Broader tape is risk-off today (S&P 500 -0.82%), which can pressure smaller/speculative names.

Financial Performance

Financial snapshot unavailable (data error: list index out of range), so latest-quarter growth trends and quarter/season cannot be assessed from the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price-target change data provided, so there’s no observable recent Wall Street sentiment shift to support a buy thesis.
Practical takeaway: without corroborating analyst upgrades/targets, the case relies mainly on technicals—which are currently mixed-to-bearish below the pivot.

Analyst Rating

Wall Street analysts forecast NNNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNNN is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 24.060

Low

Averages

High